Arsanis to discontinue phase 2 trial of pneumonia drug over futility

This article was originally published here

Arsanis said that it will discontinue its phase 2 clinical trial of ASN100 for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply